Biotest AG Skyrockets Sales by 32% in 2023 Financial Year

• Biotest AG increased sales by 32% in the financial year 2023, generating revenue of € 684.6 million compared to € 516.1 million in the previous year.
• The revenue growth is mainly due to revenue generated from technology disclosure and development services for Grifols, S.A., amounting to € 190.1 million.
• The new intravenous immunoglobulin Yimmugo had a positive impact with revenue amounting to € 27.2 million.
• The consolidated EBIT result in the 2023 financial year of € 143.5 million improved considerably compared with € -16.6 million in the previous year.
• The Biotest Group’s earnings (EAT) for the 2023 financial year amounted to € 127.0 million compared to € -31.7 million the previous year.
• For the 2024 financial year, the Board of Management is aiming for upper single-digit percentage revenue growth compared to 2023, and expects an operating result (EBIT) in a range between € 80 million and € 100 million for 2024.

The next important date, Balance sheet press conference, at Biotest is on 28.03.2024.

The price of Biotest at the time of the news was 27,60EUR and was up +2,22 % compared with the previous day.
1 minutes after the article was published, the price was 27,20EUR this corresponds to a minus of -1,45 % since publication.

Biotest

0,00 %

+0,70 %

+5,88 %

-0,69 %

-8,28 %

-1,03 %

+27,43 %

-4,69 %

+405,00 %

ISIN:DE0005227235WKN:522723

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max